Please login to the form below

Deal Watch table for May 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers during May 2013.

For an indepth analysis of these deals, read 'Pharma deals during May 2013'

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Bausch & Lomb/ Valeant	Company acquisition	Ophthalmology business	8,700
Warner Chilcott/ Actavis	Company acquisition	Branded medicines for women's health, gastroenterology, derma	8,500
Theravance/ Elan Royalty	Participation	21% of respiratory product royalties received by Theravance	1,000
Xellia/ Novo A/S	Company acquisition by Novo's VC arm	API manufacturer and anti-infective products	700
AOP Orphan/ Elan	Company acquisition	Rare disease medicines $76m sales	693
Trevena/ Forest	Option to license + equity	TRV027 phase 2 acute heart failure + $30m equity	460
Omthera/ AstraZeneca	Company acquisition	Dyslipidemia therapy end phase III	443
Abide/ Merck & Co	Licence, collaboration	Targets for Type II diabetes – 3 products	430
Okairos/ GSK	Company acquisition	Vaccine platform technology	325
Newbridge/ Elan	48 per cent company share	UAE based regional company $40m + $244m option for 52%	284
Inviragen/ Takeda	Company acquisition	Vaccines in phase I and II	250
Alexza/ Teva	Licence, supply US	Adasuve approved for acute agitation	235*
EKOS/ BTG	Company acquisition	Device for treating blood clots	220
Therasphere/ BTG	Asset purchase	Treatment for liver cancer	200
Aradigm/ Grifols	Licence + equity	Inhaled ciprofloxacin phase III ready. 35 per cent of Aradigm ($26m)	116
Ambrx/ BMS	Licence	Develop and commercialise antibody drug conjugates	112
Elan/ Speranza	Product spin out	Product spin out ELND005 phase 2 CNS drug	70**
Alvine/ Abbvie	Option to acquire	Phase II product for celiac disease	70
Cempra / Toyama	Licence, development	Solithromycin phase III	70***
Valeant / Actavis	Product acquisition	Metronidazole gel	55
Astellas / Amgen	Co-development / JV	5 Amgen development products	ND***
Nimbus / Shire	Co-development	Lysosomal storage disorder agents	ND